Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 8/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | CNR1 | P21554 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.57 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.57 |
| ▸ | MC3R | P41968 | 1/20 | 0.57 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.57 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.57 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.57 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11227138 | 0.84 | ADORA2B (0.60) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| SCHEMBL17626243 | 0.84 | SMN1; SMN2 (0.56) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| SCHEMBL21363487 | 0.84 | ADORA2B (0.64) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| SCHEMBL10112858 | 0.81 | ADORA2B (0.52) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| SCHEMBL22398942 | 0.80 | ADORA2B (0.62) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| SCHEMBL3776312 | 0.78 | ADORA2B (0.55) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| Caffeine SCHEMBL10892640 | 0.78 | ADORA2B (0.86) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| SCHEMBL7020240 | 0.76 | ADORA2B (0.62) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| Caffeine SCHEMBL28813841 | 0.76 | ADORA2B (0.83) | ADORA2BPOLBPIK3CDADORA3CNR1 | |
| Caffeine SCHEMBL6659248 | 0.76 | ADORA2B (0.83) | ADORA2BPOLBPIK3CDADORA3CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12559495-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2026-02-24 | — | — | US | disclosed |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-06-08 | — | — | US | disclosed |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-06-08 | — | — | US | disclosed |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-06-08 | — | — | US | disclosed |
| US-11555037-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-01-17 | — | — | US | disclosed |
| CN-109776537-B | Purine diones as WNT pathway modulators | 新加坡科技研究局 | 2021-12-14 | — | — | CN | disclosed |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-05-27 | — | — | US | disclosed |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-05-27 | — | — | US | disclosed |
| US-10844063-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-11-24 | — | — | US | disclosed |
| US-10844063-B2 | Purine diones as Wnt pathway modulators | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-11-24 | — | — | US | disclosed |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ELI LILLY AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ELI LILLY AND COMPANY | 2010-10-21 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7671061-B2 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| EP-1962855-A2 | TRPA1 INHIBITORS FOR TREATING PAIN | Hydra Biosciences, Inc. (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | HYDRA BIOSCIENCES (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007073505-A2 | TRPA1 INHIBITORS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11555037-B2 | Purine diones as Wnt pathway modulators | WNT1, WNT3A, WNT3 | ADORA2B 19/4885POLB 1988/4885PIK3CD 1560/4885 |
| US-20100267750-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | ADORA2B 493/4885POLB 1998/4885PIK3CD 4382/4885 |
| US-20070219222-A1 | Inhibit Transient Receptor Potential A1 (TRPA1) activity ; incontinence | TRPA1, TRPV1, TRPV2 | ADORA2B 65/4885POLB 4470/4885PIK3CD 4639/4885 |
| US-20230174533-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | ADORA2B 19/4885POLB 1988/4885PIK3CD 1560/4885 |
| US-10844063-B2 | Purine diones as Wnt pathway modulators | WNT1, WNT3A, CTNNB1 | ADORA2B 16/4885POLB 1739/4885PIK3CD 1385/4885 |
| US-20210155623-A1 | PURINE DIONES AS WNT PATHWAY MODULATORS | WNT1, WNT3A, WNT3 | ADORA2B 19/4885POLB 1988/4885PIK3CD 1560/4885 |
| US-12559495-B2 | Purine diones as Wnt pathway modulators | WNT1, CTNND1, WNT3A | ADORA2B 27/4885POLB 3128/4885PIK3CD 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.